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Abstract 
Cancer diseases are the second most common cause of death in Austria and third 
worldwide. Therefore much attention has been given to cancer research and thera-
pies over the last decades. Beside surgery and radiation therapy, chemotherapy is 
the most common treatment of cancer. In almost 50% of incidences the platinum 
based drugs cisplatin, carboplatin and oxaliplatin are used to cure the diseases. Re-
lated side effects, such as nephrotoxicity, neurotoxicity, nausea, vomiting, etc. are 
the main disadvantages. A growing chemoresistance to these classical drugs is an-
other stimulus to overcome these problems. Consequently the focus of researchers 
turned to other metal ions as coordination centres. Especially complexes of gal-
lium(III) (e.g. KP46) and ruthenium(III) (e.g. NAMI-A, KP1019), which imitate the 
properties of iron in biological systems, show promising antiproliferative activities 
even though they are less cytotoxic than the platinum based drugs. 
Another promising approach to new chemotherapeutics is the coordination of biologi-
cally active ligands to metal ions. Indolo[3,2-d][1]benzazepines (paullones) were 
found to be potent inhibitors of Cyclin dependent kinases (CDKs), enzymes control-
ling the cell cycle progression. Especially Kenpaullone exhibits an activity profile simi-
lar to Flavopiridol, which is a well known inhibitor of the CDK1-cyclinB complex. 
Nonetheless the poor bioavailability of the paullones remains a limiting factor for ap-
plication. Coordination of paullone derivatives to ruthenium and osmium resulted in 
higher solubility in aqueous media and increased cytotoxicity. However, ruthenium 
and osmium are not essential trace elements. Therefore we focused our attention on 
complexes of the biocompatible first row transition metals. 
The aim of this work was the synthesis and characterisation of copper complexes of 
paullone-based ligands, their characterisation by available techniques and cytotox-
icity tests with respect to the antiproliferative activity of the newly synthesised com-
pounds. 
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Zusammenfassung 
Krebserkrankungen stellen heute die zweithäufigste Todesursache in Österreich und 
bereits die dritthäufigste weltweit dar. Dem entsprechend hat sich auch die Krebsfor-
schung weiterentwickelt. Zu den heute angewandten Standardtherapien zählt neben 
Chirurgie und Strahlentherapie vor allem die Chemotherapie. Beinahe die Hälfte der 
Krankheitsfälle wird mit den platinhältigen Medikamenten Cisplatin, Carboplatin und 
Oxaliplatin behandelt. Die auftretenden Nebeneffekte wie Nephro- und Neurotoxizi-
tät, Übelkeit und Erbrechen zählen zu ihren großen Nachteilen. Zusätzlich können im 
Verlauf der Behandlung Resistenzen gegen die Therapeutika auftreten. Darum kon-
zentriert sich die Forschung zunehmend auf die Entwicklung von Medikamenten, die 
auf anderen Metallionen basieren, um den auftretenden Nachteilen platinhältiger 
Medikamente entgegenzuwirken. Speziell die Komplexe der dreiwertigen Ionen des 
Galliums (z.B. KP46) und Rutheniums (z.B. NAMI-A, KP1019), die Eisen in biologi-
schen Systemen nachahmen, zeigen vielversprechende antiproliferative Aktivität, 
obwohl sie weniger zytotoxisch sind als die bereits angewandten Platinverbindungen. 
Die Koordination biologisch aktiver Liganden an Metallionen ist ein ebenfalls vielver-
sprechender Ansatz. Indolo[3,2-d][1]benzazepine (Paullone) hemmen Zyklin abhän-
gige Kinasen (CDKs), Enzyme die den Zellzyklus kontrollieren. Speziell Kenpaullon 
ähnelt in seiner Aktivität Flavopiridol, einem bereits bekannten Inhibitor des CDK1-
cyclinB Komplexes. Die geringe Bioverfügbarkeit der Paullone bleibt ein beschrän-
kender Faktor. Die Koordination von Paullonderivaten als Liganden an Ruthenium 
und Osmium hat bereits zur Lösung des Problems beigetragen (höhere Löslichkeit in 
wässrigen Medien, höhere Zytotoxizität), aber da es sich bei Ruthenium und Osmium 
nicht um Spurenelemente handelt, wurde der Fokus auf Ionen von biokompatiblen 
Elementen der ersten Übergangsmetallreihe gerichtet. 
Ziel dieser Arbeit war die Synthese und Charakterisierung von Kupfer-Komplexen mit 
Paullonderivaten als Liganden, sowie Zytotoxizitätstests. 
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Abbreviations 
DNA  deoxyribonucleic acid 
CDK(s) cyclin dependent kinase(s) 
CAK(s) CDK-activating kinase(s) 
p19INK4d  protein from the INK4 family of CDK inhibitors (also known as CDKN2D) 
TF(s)  transcription factor(s) 
Ser  serine 
Thr  threonine 
ATP  adenosine triphosphate 
pRb  retinoblastoma protein 
ATC  Anatomical Therapeutic Chemical Classification System 
tf  transferrin 
ROS  reactive oxygen species 
RNR  ribonucleotide reductase 
dNTP(s) deoxyribonucleotide(s) 
IC50  half maximal inhibitory concentration 
HSA  human serum albumin 
RNA  ribonucleic acid 
PKC  protein kinase C 
NMR  nuclear magnetic resonance 
HSAB  hard and soft acids and bases 
AA  amino acid 
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1. Introduction 
Today cancer is one of the main causes of death in the world. Being the third in line 
after cardiovascular and infectious & parasitic diseases, malignant neoplasms 
caused 7.3 million deaths worldwide in 2007 – this is 13% of worldwide deceases.1 
The World Health Organization (WHO) predicts that mortality from cancer will rise 
continuously and will achieve 12 million casualties worldwide in 2030.1 
The situation is different in the industrial countries, of which Austria is chosen as an 
example. Deceases from infectious & parasitic diseases have decreased continu-
ously for decades and cause just 1% of all deaths nowadays. Cancerous diseases 
are the second most lethal diseases in Austria only outnumbered by cardiovascular 
ones. About one out of four deaths is caused by the malignant neoplasms. Conse-
quently the mortality rate is twice as high as it is worldwide. 
Worldwide 2004 Austria 2008 
Cause of death, % 
Female Male Female Male 
Cardiovascular diseases 31.5 26.8 48.0 37.3 
Infectious and parasitic diseases 15.6 16.7 0.8 0.9 
Cancer 11.8 13.4 23.1 30.0 
Table 1: Comparison of leading causes of death worldwide1 and in Austria.2 
It is noteworthy that the incidence of different types of cancer differs between the two 
genders. The leading malignomas in women are those of breast, colon, uterus and 
lung, whereas men frequently come down with cancers of prostate, colon, lung and 
bladder. It should also be mentioned in this context that between 1983 and 2006 the 
incidence of malignant neoplasms in Austria increased from 29500 to 37000 
(+25%)3, whereas the related deaths remained constant at about 19000 per year.3 
Keeping in mind all these facts it becomes clear that the fight against cancer will be a 
major task for medicinal and biochemical research for decades to come. 
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2. Carcinogenesis and Cell Cycle Control 
2.1 Carcinogenesis 
Carcinogenesis (emergence of cancer) is often a long-term process of the transfor-
mation of healthy cells into cancer cells. Its initiation starts with a single mutation in a 
gene of a differentiating cell. This DNA mutation can be induced by endogenic or 
exogenic factors. Endogenic factors are determined by genetic predisposition e.g. a 
protooncogene or a tumour supressor gene. Its mutation leads to cancerous growth. 
Protooncogenes act in a dominant manner. If a mutation takes place in a protoonco-
gene it turns into an oncogene whose protein products support uncontrolled cell pro-
liferation. Tumour suppressor genes inhibit malignant proliferation as long as they are 
not mutated too. Mutated tumour suppressor genes lose their functionality. However, 
as they act in a recessive way both alleles (genomic copies of the gene) must be 
changed first. Exogenic factors can be biological (e.g. HPV, HIV), physical (e.g. UV 
and radioactive radiation) or chemical (nutrition, smoking, asbestos, vinyl chloride, 
polycyclic aromatic hydrocarbons, etc.). They are responsible for nearly 80% of all 
incidences. 
If repair mechanisms fail and the mutation is set, initiation is irreversible and tumour 
promotion progresses. This period can last for years. Within the affected cells addi-
tional mutations accumulate during subsequent years. Thereby the cells develop al-
tered properties to make themselves capable of cancerous growth:4 Self-sufficiency 
in growth signals, insensibility to anti-growth signals, tissue invasion & metastasis, 
limitless replicative potential, sustained angiogenesis and evading apoptosis are the 
main properties of a cell capable of cancerous growth (Fig. 1a). Nonetheless, it must 
be noted that even though the mutations are irreversible, they still can be deleterious 
and lead to the death of the cells. Accordingly, it is required for the affected cells to 
maintain a determined level of genetic instability. In healthy cells, the level of genetic 
instability is low (Fig. 1b, A). As a consequence these cells are not likely to be mu-
table enough to end up as further proliferating cells when they are to hit a selection 
barrier (for instance low oxygen levels or a deficiency of proliferation signals). In tu-
mour precursor cells the level of genetic instability is higher (Fig. 1b, B). Thus it is 
probable that at least one cell will be genetically capable to overcome the barrier and 
promote the tumour progression further. The responsible genetic instability can be 
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tracked down in the lineage of the tumour. Genetic instability is too high (Fig. 1b, C), 
if deleterious mutations occur, resulting in either a slower proliferation rate or elimina-
tion of the affected cells. Consequently the tumour cell lineage can become extinct. 
   
Figure 1a: Six key properties of a cell capable 
of cancerous growth.4 
Figure 1b: Genetic instability and tumour pro-
gression.6 
 
The final step is tumour progression when a former benign tumour becomes a malig-
nant one and starts to invade the surrounding tissue (Fig. 2). Subsequently the tu-
mour has to ensure its maintenance with nutrients and thus forms blood vessels 
(angiogenesis) by itself. In later stages cells leave the primary tumour and form 
secondary tumours (metastasis) in other tissues. In 50% of human tumours prolifer-
ation is accompanied by the mutation of the tumour suppressor gene p53. It is a 
gene coding for the same-named TF involved in cell cycle control and apoptosis 
(programmed cell death). 
 
Figure 2: Benign versus malignant tumours.6 
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2.2 The Cell Cycle5, 6 
The time a cell needs to replicate and divide into two daughter cells is called the cell 
cycle. It is divided in different phases: the quiescent phase (G0), interphase (G1, S, 
G2) and the mitotic phase (M) (Fig. 3a). In G1-phase (gap) the cell grows and proteins 
necessary for DNA replication are expressed. In S-phase (synthesis) DNA is repli-
cated, and RNA and proteins are synthesised as well. G2 phase serves as prepara-
tion for mitosis (nonetheless protein and RNA synthesis is carried out in G2 phase 
too). Mitosis and cytokinesis are performed in M phase. Not all cells pass the cell 
cycle at the same speed or the same time, respectively. Liver cells for instance 
undergo mitosis just once a year, nerve cells never, but epithelial cells or the precur-
sor cells of blood cells almost once a day. Additionally, cells posses the opportunity 
to exit the cell cycle and arrest in the quiescent or senescent G0 phase. This is done 
when a cell is fully differentiated or growth factors and nutrition are present insuffi-
ciently. As long as the cell is not fully (terminally) differentiated, addition of growth 
factors and nutrition allows the cell to reenter the cell cycle. 
    
Figure 3a: The phases of the cell cycle.6  Figure 3b: The three cell cycle checkpoints.6 
 
The cell cycle is based on strict control mechanisms set between the different 
phases, as it is inevitable to finish a cell cycle phase before starting the next one (Fig. 
3b). It would be disastrous for a cell to enter S phase before finishing the synthesis of 
nucleotide building blocks in G1 phase, which are necessary for DNA replication. 
There are three checkpoints. The first in late G1 phase controls the cell’s size and the 
accuracy of the genome. If no repairs have to be carried out the cell may progress 
into S phase. The second in G2 phase reviews the newly replicated pieces of DNA on 
damages and suspends the cell cycle if necessary. The third in M phase controls the 
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distribution of the chromosome sets within the mitotic spindle. The decision whether 
a cell may pass a checkpoint or not is determined by external growth factors as well 
as by a group of intracellular protein kinases: the cyclin dependent kinases (CDKs). 
 
2.3 Protein Kinases 
There are about 850 kinases encoded within the 30000 genes of the human DNA.7 
Kinases are enzymes (biological catalysts) phosphorylating their target molecules. 
For instance binding of a kinase to a G-protein coupled receptor often induces a sig-
nal cascade within the cell, based on conformational changes of the involved proteins 
caused by targeted phosphorylation. 
Thus protein kinases constitute major pharmacological targets, as very often signal 
transduction pathways are altered in several diseases. Especially phosphorylation of 
serine, threonine and tyrosine residues exhibits a key role in inevitable functions of 
cell life. Among the Ser/Thr kinases, the CDKs are of special interest because they 
are the pacemakers of cell-cycle control.7 These kinases are dependent of assem-
bling with cyclin proteins to form an enzymatic active complex. There are thirteen 
different CDKs and 25 proteins with homology in the cyclin box encoded in the hu-
man genome.7 An example: in the middle of G1-phase the CDKs 4 and 6 associated 
with cyclin D are activated by extracellular signals. These complexes phosphorylate 
(by consumption of ATP as phosphate donor) the retinoblastoma protein (pRb). As a 
consequence pRb is inactivated. This leads to the release of the TFs E2F and DP1, 
which monitor the expression of genes necessary for the G1/S transition and S phase 
progression.7  
Now how is p53 connected to the CDKs? In normal cells p53 protein is associated 
with Mdm2 protein and its cellular level is low (Fig. 4). If DNA damages are detected, 
p53 gets phosphorylated and its cellular level rises. This activated p53 enhances the 
transcription (as a TF) of protein p21, which associates with the CDK4-cyclin D com-
plex leading to its inhibition. Thus no E2F and DP1 are released and the cell arrests 
in G1. In 50% of all cancer cells the p53 gene is mutated. Consequently the p53 pro-
tein loses its functionality and DNA damages cannot be repaired anymore (following 
this important repair mechanism). Furthermore the cell will not exit the cell cycle and 
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arrest, but progress and through mitosis 
the mutated genes will be inherited to 
the subsequent daughter cells.8 
As CDK deregulations appear frequently 
in cancers,9 much attention has been 
focused on the development of pharma-
cological inhibitors of CDKs.10 
 
 
 
 
 
3. Cancer Therapy 
Standardised medicinal treatment of cancers comprise of three therapeutic methods: 
- Surgery 
- Radiotherapy 
- Chemotherapy 
Surgery is the oldest technique. Its usage can be retraced down history, as it was 
already practiced in ancient Greece. Reasoned by more advanced means of detec-
tion (radiography, scintigraphy), surgery has become a front line method in the fight 
against cancer diseases. The unfortunate disadvantage is its limitation to solid, non-
disseminating tumours. 
In radiotherapy either X-ray or radioactive radiation is used. As in the case of surgery 
a non-disseminating, localised malignancy is necessary. It is also advantageous if 
the tumour is found close to the skin, but intraoperative radiation therapy is widely 
applied too. Nonetheless another disadvantage comes with radiation itself, as it can 
also be mutagenic. 
Figure 4:  The G1 checkpoint mechanism including 
p53. 
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Chemotherapy is the third standardised method for cancer treatment. In this context 
the term refers to antineoplastic drugs, but most generally it means the administration 
of chemicals in order to cure a disease. Classical chemotherapeutics cannot distin-
guish between healthy and malignant cells. The latter cells are in permanent need for 
nutrients as a result of their elevated metabolism. Consequently those cells will in-
corporate more nutrients, as well as more of the administrated drug than non-
affected cells. Thus tumour cells get damaged, due to their increased proliferation 
rate. Unfortunately within this principle lies the intrinsic disadvantage of this oldest 
form of chemotherapy. The most frequent appearing side effects emerge because 
there are rapidly dividing cells under normal circumstances as well. The unwantedly 
targeted cells are especially those of bone marrow, digestive tract and hair follicles. 
Thus myelosupression (decreased formation of blood cells), mucositis (inflammation 
of the lining of the digestive tract) and alopecia (hair loss) come to light. To overcome 
these problems research has been focusing lately on cellular targets especially asso-
ciated with cancer to specify future chemotherapeutics. On the other hand chemo-
therapy is the method of choice against disseminating, non-solid tumours (e.g. leu-
kaemia), which are untreatable with surgery and radiation therapy. 
The WHO classifies antineoplasitc agents according to the ATC11 code as followed: 
- Alkylating agents 
- Antimetabolites 
- Plant alkaloids and other natural products 
- Cytotoxic antibiotics and related substances 
- Other antineoplastic agents 
Alkylating agents (e.g. chlorambucil) alter the DNA’s methylation pattern. Thus gene 
expression is deleteriously changed and the affected cells go into apoptosis. Antime-
tabolites simulate metabolic structures. Consequently they compete for metabolising 
against the metabolite they imitate. Antifolates for instance compete with folic acid, 
which is an important substrate for proliferation. Plant alkaloids and other natural 
products mainly hinder mitosis by degradation of the microtubule system. An exam-
ple of cytotoxic antibiotics is dactinomycin, which is also used as an immunosuppres-
sive agent after operations. Among the several groups of other antineoplastic agents, 
monoclonal antibodies, the widely used platinum compounds or protein kinase inhibi-
tors can be found. As the main part of this work deals with synthesis and characteri-
  9 
sation of metal complexes of protein kinase inhibitor derivatives, further metal-based 
and protein-interfering agents will be discussed in more detail. 
 
3.1 Platinum-Based Compounds 
Cisplatin, cis-diamminedichloridoplatinum(II), was first synthesised by Michele 
Peyrone in mid 19th century and subsequently known as Peyrone’s chloride.12 The 
pharmaceutical potential of the complex was not known until it was discovered by 
chance in 1969 by Barnett Rosenberg.13 In a series of experiments Rosenberg exam-
ined the influence of an electric field on mitosis of bacteria. Instead of dividing, the 
bacteria (E.coli) grew to the 300-fold length, compared to bacteria growing in the ab-
sence of an electric field. Further investigations brought to light that this was not due 
to the electrical field, but due to cis-diamminedichloridoplatinum(II) and cis-
diamminetetrachloridoplatinum(IV), the platinum(IV) analogue of cisplatin (Fig. 5, 
1).14  
It took until 1978 when the FDA approved cisplatin for clinical use. Thus it became 
the first metal-based chemotherapeutic. Through its application, advanced and meta-
static testicular germ-cell cancer became highly curable. Also ovarian cancer re-
sponds strongly and furthermore cancers of lung, cervix, endometrium, bladder and 
oesophagus are treated with cisplatin. Unfortunately advanced diseases are rarely 
healable as the tumours can develop resistances throughout the therapy.15 
The mode of action of cisplatin is not fully understood yet. The biologically active 
species were proved to be the mono and diaqua species [Pt(NH3)2(OH2)Cl] and 
[Pt(NH3)2(OH2)2]2+.16 The cellular uptake of cisplatin appears to be based on diffusion 
downwards along a chloride gradient and not by transport through protein channels. 
Inside the cells, where chloride ion concentration is below 100 mM, hydrolysis sets 
in, resulting in the substitution of the chlorido ligand by a water molecule. The aqua 
species reacts with other binding partners and thus coordinates to N7 of nucleobase 
guanine and rarer adenine, hence forming 1,2-intrastrand adducts, deforming the 
double helical structure of the DNA. Consequently, as DNA repair mechanisms are 
negatively altered in cancer cells, the cells go into apoptosis. 
Unfortunately severe side effects limit the application of cisplatin. The worst of these 
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effects are nephrotoxicity (dose-limiting), ototoxicity, neurotoxicity (several cancers) 
and nausea. To overcome these secondary effects and growing resistances the 
search for other drugs was begun. Thus several platinum-based complexes were 
brought into clinical trials, but only one of these second generation platinum-drugs 
became approved worldwide (carboplatin; 2, Fig. 5)) and one (nedaplatin; 4, Fig. 6) 
regionally in Japan. Carboplatin, cis-diammine-(1,1-
cyclobutanedicarboxylato)platinum(II) differs from cisplatin in its coordination sphere.  
H3N
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O
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Figure 5. Cisplatin (cis-diamminedichloridoplatinum(II)) (1), Carboplatin (cis-diammine-(1,1-
cyclobutanedicarboxylato)platinum(II)) (2), Oxaliplatin ((1R, 2R)-diaminocyclohexane oxalatoplati-
num(II)) (3). 
 
The two chlorido ligands of cisplatin are exchanged for another leaving group, 1,1-
cyclobutanedicarboxylate. Thus the appearing side effects are different as well. My-
elosupression, especially thrombocytopenia, is the dose-limiting factor of carboplatin 
medication. In general carboplatin is less cytotoxic than cisplatin. Therefore 20-40 
times higher doses must be administered. The DNA adducts formed are the same as 
in the case of cisplatin, but their formation rate is just one tenth in contrast to that of 
cisplatin.17 
The third platinum-based antineoplastic drug approved for worldwide clinical use was 
oxaliplatin, (1R, 2R)-diaminocyclohexane oxalatoplatinum(II)18 (Fig. 5, 3), from the 
group of third generation platinum(II)-drugs. The so-called DACH ligand (diaminocyc-
lohexane), replaces the two ammine ligands of cisplatin and carboplatin. The resul-
ting complex is well soluble in water.15 The mode of action of oxaliplatin differs from 
that for the longer known platinum complexes, more precisely via the way it accumu-
lates in cancer cells.  The DNA adducts formed are the same19 as for to cisplatin, but 
oxaliplatin appears to be a better inhibitor of DNA replication.20  
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About 40 platinum(II)-based compounds entered clinical trials, but just the three de-
scribed before were approved for clinical use worldwide. Moreover just three other 
complexes were permitted nationally (Fig. 6): nedaplatin (4) in Japan, heptaplatin in 
South Korea (5) and lobaplatin in China (6). Further promising approaches focus on 
platinum(IV)-based drugs which will possibly be orally administered, due to the ki-
netic inertness of platinum(IV), whereas platinum(II)-drugs are limited to intravenous 
administration and thus connected with hospital stays for the affected people. One 
representative complex of this class of potential antineoplastic drugs is satraplatin (7, 
Fig. 6). Further trials of satraplatin application were abandoned after a clinical phase 
III study, which showed no substantial improvements in the overall survival rate.21 
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Figure 6. Nedaplatin, diammine-hydroxoacetato2--platinum(II) (4); Heptaplatin, [(4R,5R)-2(1-
methylethyl)-1,3-dioxolane-4,5-dimethamine][propanedioato2-]platinum(II) (5); Lobaplatin, [(1R,2R)-
1,2-cyclobutanedimethamine][2-hydroxypropanoato2]platinum(II) (6); Satraplatin, bis(acetate)-
ammine-dichlorido-cyclohexanamineplatinum(IV) (7)  
Efforts have also been focused on the investigation of resistances to cisplatin (and in 
lesser extent to carboplatin and oxaliplatin). The current knowledge concerning this 
subject was summarized in a review by Heffeter et al.22 Based on the encountered 
restrictions accompanying the application of platinum-based drugs, researchers 
turned their attention to the development of novel metal-based agents. 
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3.2 Gallium-, Ruthenium- and Osmium-based Compounds 
Currently applied platinum-based antineoplastic drugs face, additionally to the ap-
pearing side effects, commonly a growing resistance throughout their administration 
during chemotherapy in order to cure human cancer diseases at a disseminated 
state. The phenomena of “acquired” and “intrinsic” drug resistance of tumours is a 
serious problem. Acquired resistances are based on the tumour cells’ genetic insta-
bility, which allows a quick adjustment to chemotherapeutic lesions. Intrinsic resis-
tances reflect properties of the tissue the tumour originated from. Especially epithelial 
cells are known to be protected against a life-long exposure to venoms.22 As a natu-
ral consequence of these problems other prospective metal-based drugs have been 
designed, in order to reduce the platinum-linked side effects and to avoid the devel-
opment of resistances.23, 24 
 
3.2.1 Gallium 
Gallium has been in frequent use for imaging in medicine. Its radioactive isotopes 
67Ga and 72Ga concentrate in several tumour tissues, thus making gallium isotopes 
valuable tumour markers for radiation therapy as well.25-27 In chemical respect Ga3+ 
imitates Fe3+ in many ways, for instance in electric charge, ionic radius and coordina-
tion number. Compared to the Fe2+/Fe3+ redox-pair, Ga3+ exhibits no redox-activity 
under physiological conditions. Consequently it lacks a property significant for the 
role of iron in biological systems. Simulating the latter, Ga3+ is transported by trans-
ferrin (tf) protein as well and thereby enters cells embedded into this protein (tf binds 
to the tf receptor and is channelled into the cell susbsequently). 
Cancerous cells are under permanent oxidative stress, due to their highly increased 
metabolism. Oxidative stress is caused by reactive oxygen species (ROS), which are 
side products of biologically occurring redox-processes. Hydrogen peroxide, super-
oxid and hydroxyl radicals belong to ROS. Natural systems have developed redox-
proteins with embedded metal ions to handle metabolic redox-processes, as well as 
ROS. The functionality of these proteins is based on the redox-properties of the em-
bedded metal ions, for instance Fe2+/Fe3+ or Cu+/Cu2+. It is required that the redox 
potential of a redox-pair is accessible under physiological conditions (as it is for the 
two given before). 
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The increased metabolism of tumour cells requires more redox-proteins and thus 
higher amounts of the associated metal ions. To accumulate these metal ions, malig-
nant cells express more receptors, i.e. tf receptor. The cellular uptake into the tumour 
of Fe3+ is accompanied by uptake of Ga3+. Again the higher consumption of nutrients 
(in this case especially iron) by malignant cells (compared to normal ones) is respon-
sible for the accelerated accumulation of Ga3+ in the tumour. 
It is commonly agreed that the major cellular 
target of Ga3+ is the enzyme ribonucleotide re-
ductase (RNR, Fig. 7). This enzyme catalyses 
the reduction of ribonucleotides to deoxyribonu-
cleotides (dNTPs), which are building blocks for 
DNA. Gallium substitutes the two Fe3+ ions in 
the active site of RNR, resulting in the enzyme’s 
inhibition. 
The first gallium-based compounds to enter 
clinical trials were gallium chloride, GaCl3, and 
gallium nitrate, Ga(NO3)3.29 As the last interacts 
with blood calcium levels, it was approved for the treatment of cancer associated hy-
percalcemia subsequently. Additionally occurring side effects such as nephrotox-
icity30, 31 (short treatment) and optic neuropathy and blindness32 (continuous treat-
ment) precluded further applications of gallium nitrate. Gallium chloride was with-
drawn from clinical trials because of insufficient bioavailability.33 
Gallium(III) complexes (Fig. 8) gallium maltolate (tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium(III); 8) and KP46 (tris(8-quinolinolato)gallium(III); 9) appear to be more 
promising. Both compounds were synthesised for oral administration and are cur-
rently in clinical evaluation.34 Thereby gallium maltolate has been tested versus re-
fractory prostate cancer and multiple myeloma in a series of clinical phase I tests.35 
The same is true for KP46 which was tested against several refractory tumours.36 
The complexes differ from the salts in their behaviour in biological environment. 
Figure 7. Human RNR, subunit M2 B28 
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Figure 8. Gallium maltolate, tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III) (8) and KP46, 
tris(8-quinolinolato)gallium(III) (9) 
 
Gallium maltolate dissociates in the blood stream due to hydrolysis and the gallium 
ion is bound to transferrin subsequently. KP46 remains stable under the same cir-
cumstances and thus must follow a different way of absorption into the tumour.34 
Nonetheless bioavailability of the complexes remains manifold higher compared to 
the salts37-39 and dose-limiting side effects do not appear.35, 36 
Paullone-based ligands also were coordinated to Ga3+, but insufficient solubility in 
biological media precluded their further development.40, 41 
 
3.2.2 Ruthenium 
Ruthenium is a second row transition metal placed below iron and above osmium. As 
osmium it belongs to the noble metals and consequently its chemical and physical 
properties differ from those of iron substantially. In contrast to iron the available oxi-
dation states vary from +VIII to –II, with +II and +III as the most frequently appearing 
ones. Furthermore it is a chemically inert metal with respect to mineral acids. It is just 
soluble in aqua regia above 100°C. Of its seven natural isotopes 99Ru and 101Ru can 
be used for NMR measurements.42 
Nonetheless ruthenium’s vicinity to iron and its noble metal properties (related to 
platinum) make it an interesting candidate for metal-based drug development. Addi-
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tional features concerning the metal’s chemistry which play a role for the develop-
ment of ruthenium-based antineoplastic agents are:24 
- well known coordination chemistry and synthetic pathways, 
- coordination geometry (octahedral), 
- physiologically available oxidation states +II, +III, +IV, 
- the ability to mimic iron in biological systems, 
- a favourable ligand exchange rate. 24 
From the group of Ru(III) complexes, the most promising agents NAMI-A (imida-
zolium trans-[tetrachlorido(1H-imidazole)(DMSO)ruthenate(III)]; 10, Fig. 9) and 
KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]; 11, Fig. 9) 
have successfully passed clinical phase I trials and have begun (NAMI-A)43, or are 
entering (KP1019)44,45 phase II studies. 
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Figure 9. NAMI-A, imidazolium trans-[tetrachlorido(1H-imidazole)(DMSO)ruthenate(III)], (10) and 
KP1019, indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (11) 
 
These complexes are administered intravenously. Consequently they are dependent 
from transport proteins in the blood stream to reach their biological target. In contrast 
to gallium, these ruthenium(III)-drugs are preferentially bound to HSA45 and only par-
tially to transferrin.46 Furthermore these complexes are thought to be pro-drugs, as 
their mode of action is described by the approach of “activation by reduction”47 and 
thus they are categorised as functional compounds.48 The permanent need for nutri-
ents, due to high proliferation rate, accompanied by chaotic angiogenesis, put tumour 
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cells in a hypoxic state. As a result the primary energy source is anaerobic glycolysis 
yielding elevated amounts of lactate, which in its turn decreases the pH (acidifying) in 
the surrounding media.48 In this more acidic environment the Ru(III) can be reduced 
by e.g. GSH or electron transfer proteins. Under these circumstances the t2g orbitals 
of Ru(III) get filled, consequently elevating the electron density of the central metal 
ion and thus making the chlorido ligands replacement by water molecules easier. The 
intracellular targets of the compounds are thought to be DNA (N7 of guanine),49 to-
poisomerases (inhibition) and mitochondria (direct interaction). Furthermore the 
complexes could be responsible for creation of ROS and are under investigation as 
metastasis inhibiting agents.50 
Organo ruthenium(II) complexes have been developed recently. A special feature is 
the presence of a η6-arene ligand24,51 Compounds of this kind adopt a “three-leg” pi-
ano-stool geometry (Fig. 10). 
 
Figure 10. ‘Piano-stool structure’ of Ru(II)-arene complexes.  
Generally the antiproliferative activity of these complexes can be tuned by the choice 
of appropriate ligands. In particular: several well known Ru(II)-piano-stool com-
pounds were compared in vitro on A2780, an ovarian cancer cell line. The coordi-
nated η6-arenes differed from each other, but the other ligands remained the same. 
The complexes showed large differences in their antineoplastic activity profile. Co-
ordination of e.g. tetrahydroanthracene decreases the IC50-value of one complex 
twentyfold compared to coordinated p-cymene, which is the η6-arene of choice as it 
exhibits a balance between cytotoxicity and solubility in biological media.52 Of course 
cytotoxicity of the complexes can be tuned by derivatising the other three ligand posi-
tions. Thereby the generally pursued concept yields complexes with one mono- or 
bidentate ligand and two or one halides bound to the ruthenium(II), correspondingly. 
The halide part commonly forms the leaving group, whereas tuning of cytotoxicity is 
accomplished by means of the other ligand(s). Of the monodentate ligands the 
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RAPTA types are the most known. Bidentate ligands of the N,N-, N,O-, P,N-, S,O- or 
O,O- types were used. Paullone-based bidentate N,N-ligands with a bidentate N,N 
binding side have been coordinated to ruthenium(II) as well, but to them it will be re-
ferred later.53-55 
 
3.2.3 Osmium 
Generally its characteristics resemble those of ruthenium. As the latter, it is a noble 
metal and can be found in oxidation states from +VIII to –II as well. Unlike iron, the 
preferred oxidation state of osmium is +IV. Seven natural isotopes are known. Of 
those, 187Os and 189Os can be used for NMR measurements.42 
Several properties distinct it from ruthenium, making it another interesting coordina-
tion centre.42 Especially the altered ligand exchange kinetics, resulting from a 
stronger π-back donation of lower oxidation states and the much stronger spin-orbit 
coupling, are the most interesting features. It has been shown for complexes of the 
type [M(maltolato)(H2O)]+ (with M = Ru, Os) that the pKa-values of the osmium com-
plex is much lower, compared to its ruthenium analogue.56 This is of importance, as 
the biological pH is about 7.40. As a result osmium complexes are more easily de-
protonated in biological media than the ruthenium complexes. Deprotonation yields 
the less reactive [Os(maltolato)(OH)].56 An osmium(II) η6-arene (p-cymene) complex, 
with a paullone-based ligand, exchanges a chlorido ligand for an aqua ligand, within 
72 h, only half as much as its ruthenium analogue, but thereby almost immediately 
reacting further to the hydroxo complex. The ruthenium analogue will exchange a 
chlorido ligand for an aqua ligand much faster, but the aqua complex shows no fur-
ther sign of deprotonation.55 
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4. Cyclin-Dependent Kinases (CDKs) and Their Inhibitors 
In the last years, research on CDKs, their regulators and substrates has been carried 
out in order to understand the regulation of the mammalian cell cycle.58 The princi-
ples of the mode of action of CDKs are outlined in Chapter 2. For a better under-
standing of the role of CDK inhibitors, further detail will be given below. 
Cyclins are produced at certain phases of the cell cycle. They periodically appear at 
the same stages of consecutive cycles. In addition, to the central role CDKs play in 
the cell cycle progression, members of this protein family have been associated with 
other potential roles. One of these roles is thought to be a CDK-regulating function, 
performed by the group of CDK-activating kinases (CAKs).59 CAKs control the activity 
of CDKs by phosphorylation of specific Ser and Thr residues, needed for proper func-
tioning. Additionally, several CAKs are able to phosphorylate the C-terminal domain 
of RNA polymerase II and thus control the transcription of cell cycle progression 
propagating proteins.60 
 
4.1 The Role of Different CDKs in Cell Cycle Regulation 
As mentioned before, progression through G1 phase is controlled by CDK4, CDK6 
and the corresponding cyclin regulators. Quite recently, the additional contribution of 
CDK2 has been also elucidated.9,61 At the beginning, mitogens (proteins, activating 
signal transduction pathways) initiate synthesis of D-type cyclins and probably regu-
late the required folding and channelling of CDK4 and/or CDK6 into the cell nucleus 
as well. The active complexes target members of the retinoblastoma (Rb) protein 
family (e.g. pRb) and accomplish phosphorylation. The members of the Rb family 
possess multiple phosphorylation sites for CDKs (e.g. 16 in pRb), but only some of 
them are recognized by CDK4-cyclinD and/or CDK6-cyclinD complexes.58,62 As al-
ready outlined before, phosphorylation of pRb leads to the expression of E2F tran-
scription factor.63 Furthermore Rb proteins and E2F form active complexes, whose 
role is the enhancement of E-type cyclin expression, which are thought to be the ac-
tivators of CDK2. The latter regulates the completion of G1 phase and is presumably 
responsible for the final degradation of CDK2-cyclinE as well. From this point in G1 
onwards (‘restriction point’), the cells are believed to become independent of mito-
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genic signals and cell division is continued without these stimuli.9 Furthermore CDK2-
cyclinE is thought to be essential for initiation of DNA replication, but as soon as the 
cell enters S phase, the enzyme needs to be deactivated. This is realised by degra-
dation of cyclin E by an enzyme from the family of ubiquitin ligases and the subse-
quent segmentation by the proteasome.64 The liberated CDK2 is bound to A- and B-
type cyclins facilitating S phase transition. At the end of S phase, CDK2-cyclinA 
complexes are joined by CDK1-cyclinA complexes. The specific roles of these two 
species concerning S-G2 transition remains unclear.58 However, it is known that on 
the one hand cyclinA is degraded during G2 and cyclinB is synthesised instead. On 
the other hand CDK1-cyclinB complexes enhance G2-M transition and progression 
through cell division.65 Additionally, these enzyme complexes promote centrosome 
separation and are involved, for instance, in chromosomal condensation and break-
down of the nuclear lamina. Finally, the cell cycle comes to its end. To ensure that 
the exit from mitosis is performed accurately, CDK1-cyclinB complexes are degraded 
via ubiquitination by the anaphase-promoting complex (proteolytic pathway).58,66 
 
4.2 CDK Inhibitors 
Determination of primary, secondary and ternary structures67 of CDKs has contri-
buted primarily to the synthesis of the first inhibitors of these enzymes. First of all, it 
was found68 that there are differences between the ternary structures of CDK2 in as-
sociation with ATP69 and the complex formed by CDK2, cyclin and ATP,70 thus pro-
viding information about the conformational changes of the species on their associa-
tion into the active complex. The influence of the natural inhibitors of CDKs on the 
conformation of the enzyme was also investigated. Furthermore the structures of p21 
and p19INK4d could be established by X-ray diffraction71 or NMR spectroscopy, re-
spectively.72 The protein p19 was also co-crystallised with CDK6. Thereby the active 
centre of the complex was located in the catalytic cleft between the two domains.73 
From these structural information three major approaches to the inhibition of CDKs 
were derived: 
- Competitive inhibitors to ATP, 
- Non-competitive inhibitors which use the same binding site as the natural ones, 
- Molecules utilising both ways. 
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The first synthetic attempts took into account similarities of already known inhibitors 
of related protein kinases (Fig. 11), e.g. SU5416 (Semaxanib, (3Z)-3-[(3,5-dimethyl-
1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; 12) which is a more ad-
vanced tyrosine kinase inhibitor. In further experiments some already well known 
drugs, such as the protein kinase C (PKC) inhibitor Staurosporine 
((9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-
(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-
j][1,7]benzodiazonin-1-one; 13) showed significant CDK inhibition potential.74-76 
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Figure 11. SU5416, (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one (12); 
Staurosporine, (9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11(methylamino)-
9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one (13)  
From the group of flavonoids, e.g. flavopiridol (2-(2-chlorophenyl)-5,7-dihydroxy-8-
((3R,4S)-3-hydroxy-1-methylpiperidin-4-yl)-chromen-4-one, 14, Fig. 12), a non selec-
tive kinase inhibitor, exhibits noteworthy antiproliferative activity against CDKs in 
vitro.77-80 The flavone core is the structural template, which is expanded by a piperi-
dine unit in position 8 and an aryl substitution in position 2. By in vivo testing in mice, 
selective apoptosis of cells in the lymph nodes, the spleen and the thymus was ob-
served, when administered daily as an intra venous bolus.81 
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Figure 12. Flavopiridol, 2-(2-chlorophenyl)-5,7-dihydroxy-8-((3R,4S)-3-hydroxy-1-methylpiperidin-4-
yl)-chromen-4-one (14); Kenpaullone, 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepine (15); 
Valium® (16). 
Paullones exhibit an activity profile similar to that of flavopiridol. The leading com-
pound, 9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepine (Kenpaullone; 15, Fig. 12), 
was found to be an inhibitor of CDK1-cyclinB and CDK2-cyclinE complexes.82 The 
first successful synthesis of paullones was described in 1991.83 Thereby benzaz-
epine carboxylic acid esters were decarboxylated upon heating in DMF, with forma-
tion of 3,4-dihydro-1H-benz[b]azepine-2,5-dione. This underwent Fischer indol syn-
thesis, yielding 7,12-dihydroindolo[3,2-d][1]benzazepine or its 9-bromo-substituted 
analogue kenpaullone (Fig. 13). Primarily the aim of paullone development was the 
improvement of already approved structural analogues, e.g. diazepam (Valium ®; 16, 
Fig. 12). 
 
Figure 13. Synthesis of (the first) paullones. 
The benzazepine dione was tested for its antiproliferative activity.85,86 Paullones were 
also screened for antineoplastic properties in sixty human tumour cell lines at the 
NCI. This family of compounds is named after the designer of the screening algor-
ithm (COMPARE), Kenneth Paull.87 
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Further structure-activity studies showed that the lactam unit of the azepine ring is 
essential for CDK inhibition, due to steric reasons.88 Nonetheless other intracellular 
targets could be identified as well, e.g. glycogen synthase kinase 3β (GSK-3β)89-91 
and sirtuins.92,93 The first inhibits GSK by phosphorylation and plays a role in cell 
cycle control as well. The second appears to be a regulator of p53 and associated 
with ageing and pathogenesis of viral and cancerous diseases. Especially substitu-
tion at the lactam unit seems to enhance the inhibiting properties of paullones to-
wards sirtuins. 
The poor solubility of paullones in aqueous and biological media remains a hurdle to 
be overcome. Therefore many derivatives have been synthesised in order to in-
crease water solubility and anitproliferative activity as well. A promising approach is 
the derivatisation of the indolo benzazepine core structure, thus forming chelating 
binding sites for metal ions. Several complexes of paullone-based ligands to different 
metal ions are displayed in Fig. 14. 
To perform modifications at the lactam unit, the latter must be activated first. There-
fore the oxygen in position 6 is exchanged with sulfur by thionation, yielding the ap-
propriate thio-lactam, which can be further derivatised with amines.  To preserve the 
lactam unit, other ligands, with binding sites originating from paullone carbon C9, 
have been synthesised too. All these synthetic approaches are well known in the lit-
erature and some of them are described in the General Part. 
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Figure 14. Paullone-based complexes of Ga3+, Ru2+ and Os2+ developed throughout the last decade. 
The development of gallium complexes is no longer followed because the problems 
with their solubility in aqueous media and stability could not be overcome. Com-
plexes of ruthenium and osmium are still under development. 
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5. Copper 
Copper is an element of the first group of transition metals. Along with silver and gold 
it belongs to the coin metals, a name which is derived from the ability of these metals 
to resist to corrosion. The name copper is derived from Latin “aes cyprium”, which 
can be translated as “ore of Cyprus”, as mines on Cyprus were exploited already in 
ancient times. About 3000 b.c. the advantageous properties of the binary alloy of 
copper and tin was discovered, consequently naming the upcoming age after the al-
loy – the Bronze Age.42 
The natural isotopes of copper, namely 63Cu and 65Cu, make it accessible to NMR 
spectroscopy methods. Its electronic configuration is [Ar]3d104s1, its preferred oxida-
tion states are +1 (d10, diamagnetic) and +2 (d9, paramagnetic).42 
Salts of copper(I) disproportionate in aqueous solutions to copper(II) and copper, due 
to the much higher hydration energy of the copper(II) ion. Consequently, only com-
pounds of copper(I) which are insoluble or stable as complexes, do not undergo dis-
proportionation. Differing from [Cu(H2O)4]+, which disproportionates into Cu and 
[Cu(H2O)6]2+, [Cu(NH3)2]+ is a linear and stable ion, originating from the compropor-
tionation of Cu and [Cu(NH3)6]2+. In solution with concentrated ammonia, copper(I) 
forms the complex ion [Cu(NH3)4]+, with tetrahedral geometry, as well. In contrast to 
copper(II), which prefers an octahedral coordination sphere in crystals and com-
plexes as well, copper(I) is more likely to be found in tetrahedral geometry. Copper(II) 
complexes are a subject of the so-called Jahn-Teller effect. This theorem describes 
an electronic effect, which appears in non-linear molecules with a degenerated elec-
tronic ground state, yielding a geometrical distortion of the coordination polyhedron, 
thus resulting in a removal of degeneracy and a decrease of the overall energy of the 
complex. As a consequence, several copper(II) complexes are additionally coordi-
nated by two aqua ligands in the axial positions above and below the square plane of 
coordination: [Cu(H2O)6]2+, [Cu(NH3)4(H2O)2]2+. In crystals of copper(II) compounds 
the distortion can be found preferentially as a elongation and rarely as a compression 
of the octahedron. It should be mentioned as well, that copper(II) compounds are, 
due to the d9 electronic state, brightly coloured, whereas copper(I) compounds are 
usually colourless. The potential difference, between these two oxidation states, 
make copper a valuable metal for redox processes occurring in biological systems.42  
  25 
5.1 Copper in Biological Systems 
For most aerobic organisms copper is an essential trace element. An average adult 
male contains about 100 mg of the metal.94 It serves as a catalytic and structural co-
factor for enzymes involved in energy production, oxygen transport, cellular metabo-
lism, signal transduction, blood clotting and many other processes.95 In molluscs and 
crabs the copper containing protein haemocyanin is responsible for the transport of 
oxygen.42 As mentioned before, under physiological conditions, copper can exist in 
its oxidation states Cu+ and Cu2+. Each ion is distinct from the other by its specific 
coordination chemistry. The fully occupied d-orbitals of Cu+ (d10) make it a “softer” ion 
according to the HSAB principle, whereas Cu2+ is a “harder” coordination centre 
compared to Cu+. Thus Cu+ prefers “softer” ligands (e.g. sulfur donors), and Cu2+ is 
more likely to bind with “harder” ligands (nitrogen or oxygen donors), respectively. 
Thus proteins coordinated to Cu+ preferentially bind via sulfur containing amino acid 
side chains of cysteine or methionine, whereas Cu2+ more likely bound through the 
nitrogen or oxygen bearing amino acid side chains of histidine (N) or glutamate (O) or 
aspartate (O).96,97 As a result copper is facilitating an unexpectedly high number of 
biological processes. One of the most prominent representatives of the group of 
metal-based enzymes: the Cu/Zn superoxide dismutase (SOD1, Fig. 15), which cata-
lyzes the disproportionation reaction of 
metabolic side product superoxide into 
dioxygen or into hydrogen peroxide if the 
milieu is acidic. Thereby Cu2+ gets re-
duced to Cu+. It should be mentioned in 
this context, that it is of central importance 
to biological systems to possess a func-
tioning system for metal ion absorption 
and distribution to the appropriate targets, 
as otherwise free metal ions are likely to 
exhibit their redox activity in places unwanted. Thus they are likely to undergo Fenton 
type reactions with hydrogen peroxide, yielding even more reactive oxygen species. 
Other defects in the homeostasis of copper are directly correlated with human dis-
eases. For example, mutations in the P-type ATPases ATP7A and ATP7B (ATP 
driven Cu+ pumps), expressed in extrahepatic tissues or in the liver, respectively, are 
responsible for the occurrence of Menkes and Wilson’s disease.95 
Figure 15. Structure of human Cu/Zn SOD.98 
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In eukaryotic cells, copper acquisition is enhanced by the integral membrane protein 
Ctr1. The protein consists of three transmembrane domains. Three proteins associ-
ate as a homotrimer, likely to form a pore for copper import.99-102 The structure of 
Ctr1 is structurally and functionally conserved from yeast to humans.103-105 The re-
sults of further research strongly suggest, that the pore is highly affine to Cu+, as Ctr1 
only reaches its maximal activity in the presence of cell surface Cu2+/Fe3+ metallore-
ductase Fre1 and Fre2,106 but it remains yet unclear how Cu+ is preserved in its oxi-
dation state in the presence of oxygen before Ctr1 mediated import. Ctr1 plays a role 
in intracellular mobilisation of copper storages as well. Additional transporters e.g. 
Ctr2 or Ctr6 could be identified in S.cervisieae (baker’s yeast) or S.pombe (fission 
yeast), respectively.106-109 On the one hand the details of transport are still topic of 
discussions,95 but on the other hand copper transport to mitochondria and integration 
into cytochrome c oxidase (Fig. 16) has been studied excessively.111 
 
Figure 16. Structure of human cytochrome c peroxidase. 
The chaperone protein Cox17 appears to be the protagonist, responsible for cyto-
chrome c oxidase assembly. The latter is a key enzyme of the mitochondrial respira-
tory chain, the final step in the main way of energy generation in aerobic cells. In-
volved in this important process of cellular life, copper became a popular target for 
drugs, as well as a mediator of drugs, being a centre of coordination. 
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In conjunction with the topic of this thesis, especially the role of copper compounds in 
cancer therapy will be dealt with. 
 
 
5.2 Copper in Cancer Treatment 
In relation with cancer, many clinical trials have shown that the concentration of cop-
per is elevated in the serum, as well as in the tumour.112 Furthermore copper is 
thought to be another stimulating factor of angiogenesis (next to other growth fac-
tors).113-115 Consequently, copper is required for uncontrolled proliferation of malig-
nant neoplasms. 
One approach to cancer treatment through copper is the administration of copper 
chelating ligands, e.g. D-penicillamine (D-pen).112 This possible drug benefits from 
the elevated level of oxidative stress in tumours. As it reduces Cu2+, yielding Cu+ and 
a D-pen radical it contributes to the formation of ROS. The formed Cu+ does the 
same, as its oxidation back to Cu2+ yields a superoxide anion. Thus the oxidative 
stress is increased continuously, finally reaching a lethal level, leading the cancer cell 
to apoptosis. 
A second approach is the same as described for gallium(III) and ruthenium(III). The 
excessive need of tumours for nutrients leads to a higher acquisition of metal ions, 
compared to normal cells. As the same is true for copper, copper chelators have 
been of frequent interest as potential anti-tumour drugs. Up to present day many 
compounds have been tested. Several well-known bis(thiosemicarbazones) and their 
copper(II) complexes show encouraging anti-tumor activity, which has been demon-
strated by both in vitro and in vivo experiments,116-117 as well as copper(II) complexes 
of purine derivatives, benzohydroxamic acid, imidazole derivatives and polycarboxy-
lates have been synthesised, characterised and tested for cytotoxicity.57 
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General Part 
Within this work novel complexes of copper(II) with paullone-based ligands have 
been synthesised, characterised and tested for antiproliferative activity in vitro. The 
results of these studies have been summarised in a paper submitted to Inorganic 
Chemistry. The manuscript submitted follows in the next section and is formatted ac-
cording to the guidelines for authors of the journal. 
 36 
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Abstract 
The reaction of copper(II) chloride or copper(II) acetate with 6-N-(2-N´,N´-
dimethylaminoethylamino)-7,12-dihydroindolo-[3,2-d][1]benzazepine (HL1), 9-bromo-6-N-
(2-N´,N´-dimethylaminoethylamino)-7,12-dihydroindolo-[3,2-d][1]benzazepine (HL2),  N-(9-
bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden-N’-(1-pyridin-2-yl-
methylidene)azine (HL3) or N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-
yliden-N’-(1-pyridin-2-yl-ethylidene)azine (HL4) in methanol affords the novel copper(II) 
complexes [Cu(HL1)Cl2] (1), [Cu(HL2)Cl2] (2), [Cu(HL3)Cl2]·1.5CH3OH (3), 
[Cu(HL4)Cl2]·1.5H2O (4) and [Cu(HL4)(CH3COO)(CH3OH)]·3CH3OH (5). The new ligands 
(HL2 and HL3) and the complexes 1−5 were characterized by 1H NMR, 13C NMR, IR and 
electronic absorption spectroscopy, ESI mass spectrometry and X-ray crystallography. Two 
ligands, HL1 and HL2, and complexes 1−4 were tested for cytotoxicity in three human cancer 
cell lines, namely CH1 (ovarian carcinoma), A549 (non-small cell lung cancer) and SW480 
(colon carcinoma). Additionally, complexes 1, 2 and 4 were assayed in an isogenic pair of 
ovarian cancer cell lines, one being sensitive to cisplatin (A2780) and the other having 
acquired cisplatin resistance (A2780cisR). All of the compounds evaluated are cytotoxic, with 
complexes 3 and 4 exhibiting IC50 values in the nanomolar range.    
 
Introduction 
Many anticancer drugs used today are either classical non-targeted coordination complexes or 
organic intercalators, but they are increasingly used in combination with targeted organic 
compounds that inhibit specific enzymes. In recent years, efforts to construct hybrid drug 
systems in which a targeted organic drug is attached to a non-targeted metal center have 
emerged.1 Indeed, metal complexes with biologically active ligands display many favourable 
properties that could overcome the limitations encountered in combination therapies.2− 13 In 
this regard, recent efforts by us have focussed on the synthesis of metal complexes with 
indolo[3,2-d]benzazepines (Paullones), which inhibit the activity of cyclin-dependent kinases 
(CDKs) and show high cytotoxicity in vitro.14,15 Structure–activity relationship studies on 
metal-free compounds have revealed certain features required for CDK-inhibitory properties 
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that do not necessarily parallel their antiproliferative activity profile.16 As a result, other 
intracellular targets for Paullones have also been suggested.15,17 Our primary aim has been to 
investigate the effect of metallation of Paullone compounds on both CDK-inhibition and 
cytotoxicity. Since the original Paullone derivatives do not contain binding sites to 
accommodate metal ions, a number of novel indolo[3,2-d]benzazepines have been designed 
and synthesized and subsequently coordinated to gallium(III), ruthenium(II) and osmium(II) 
centers.18− 21 The effect of metal coordination on the aqueous solubility, antiproliferative 
activity and impact on the cell cycle has been reported.18−21 As a natural extension to this 
work, we turned our attention to ligands that are able to bind copper(II), as a more 
biologically compatible metal ion.  
Copper is an essential element for most aerobic organisms, employed as a structural and 
catalytic cofactor, and consequently it is involved in many biological pathways.22 − 25 Taking 
this into account, much attention has been given to research on the mechanisms of 
absorption,26− 28 distribution,29− 31 metabolism and excretion of copper,32− 34 as well as on its 
role in the development of cancer and other diseases.35,36 In the case of cancer, numerous 
studies have shown that the concentration of copper is elevated in the serum, as well as in the 
tumor,24,37− 51 as copper is an endogenous angiogenesis stimulator.52− 54 Nevertheless, 
several bis(thiosemicarbazones) and their copper(II) complexes show encouraging anti-tumor 
activity, which has been demonstrated in vitro and in vivo.55,56 Moreover, a number of 
copper(II) complexes with purine-based, benzohydroxamic acid, imidazole and 
polycarboxylate ligands have been shown to exhibit good cytotoxicities.57  
Herein we report on the synthesis of the first Paullone-based copper(II) complexes of the 
general formulae [Cu(HL1–4)Cl2] and [Cu(L4)(CH3COO)(CH3OH)], where HL1 and HL2 are 
bidentate ligands and HL3 and HL4 tridentate ligands (Scheme 1). Their spectroscopic 
properties, solid state structures, and cytotoxicity in human cancer cell lines are also reported. 
 
Scheme 1. Synthesis of 1−5 a and relevant numbering scheme. Underlined compounds have 
been characterized by X-ray crystallography. 
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a Reagents and conditions: (i) N,N-dimethylethylenediamine, THF, Ar, reflux, 24 h (HL1, 60%) or 45 h (HL2, 
68%); (ii) CuCl2⋅2H2O, CH3OH, reflux, 30 min [68% (1), 69% (2)]; (iii) N2H4⋅H2O, C2H5OH, reflux, 1.5 h 
(85%); (iv) 2-pyridinecarbaldehyde, CH3OH, reflux, 45 min (HL3 68%) or 2-acetylpyridine, CH3OH, reflux, 3.5 
h (HL4 73%); (v) CuCl2⋅2H2O, CH3OH, reflux, 30 min [95% (3), 91% (4)]; (vi) Cu(CH3COO)2·H2O, CH3OH, 
reflux, 30 min (83%) (5). 
 
 40 
 41
Experimental 
Starting Materials. 7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-thione (A),58 9-bromo-
7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-thione (B),17 9-Bromo-7,12-
dihydroindolo[3,2-d][1]benzazepin-6-ylhydrazine (C),20  6-N-(2-N´,N´-
dimethylaminoethylamino)-7,12-dihydroindolo-[3,2-d][1]benzazepine (HL1) 59 and N-(9-
Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden-N’-(1-pyridin-2-yl-
ethylidene)azine (HL4) 60 were prepared according to published protocols. Tetrahydrofuran 
and ethanol were dried using standard procedures. Methanol (HPLC grade) was purchased 
from Fisher Scientific. Hydrazine hydrate, N,N-dimethylethylenediamine, 2-
pyridinecarbaldehyde, 2-acetylpyridine and copper(II) chloride were purchased from Sigma-
Aldrich and used without further purification. 
9-Bromo-6-N-(2-N´,N´-dimethylaminoethylamino)-7,12-dihydroindolo-[3,2-
d][1]benzazepine (HL2). To 9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-thione 
(B) (1.01 g, 3.0 mmol) in dry THF (60 ml), N,N-dimethylethylendiamine (0.38 ml, 3.5 mmol) 
was added and the reaction mixture was heated to reflux under argon for 45 h. Afterwards the 
solvent was evaporated and the solid residue extracted with diethyl ether (120 ml). The 
filtered extract was evaporated to ca. 50% of the initial volume and allowed to stand at −20 
°C overnight. The colorless crystals formed were removed by filtration, washed with diethyl 
ether and dried in vacuo. Yield: 0.78 g, 68%. Anal. Calcd for C20H21N4Br (Mr = 397.31 
g/mol) (%): C, 60.46; H, 5.33; N, 14.10. Found: C, 60.52; H, 5.63; N, 13.78. 1H NMR 
(DMSO-d6, δ): 11.61 (s, 1H, N12), 7.84 (s, 1H, C8), 7.68 (d, 1H, 3J(HC2) = 7.5 Hz, C1), 7.36 
(d, 1H, 3J(HC10) = 8.5 Hz, C11), 7.25 (dd, 1H, 3J(HC2) = 8.5 Hz, 3J(HC4) = 8.0 Hz, C3), 7.23 
(d, 1H, 3J(HC11) = 8.5 Hz, C10), 7.14 (t, 1H, 3J(HC14) = 5.0 Hz, N13), 7.13 (d, 1H, 3J(HC3) = 
8.0 Hz, C4), 7.03 (dd, 1H, 3J(HC1) = 7.5 Hz, 3J(HC3) = 8.5 Hz, C2), 3.32 (s, 2H, C7), 3.28 (dt, 
2H, 3J(HN13) = 5.0 Hz, 3J(HC15) = 6.5 Hz, C14), 2.15 (s, 6H, C17+C18); 13C{1H} NMR 
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(DMSO-d6, δ): 155.52 (C6), 147.25 (C4a), 136.78 (C11a), 136.24 (C12a), 129.09 (C7b), 
128.36 (C4), 128.23 (C3), 127.42 (C1), 124.49 (C10), 122.59 (C12b), 121.07 (C2), 121.00 
(C8), 113.96 (C11), 112.01 (C9), 109.31 (C7a), 58.61 (C15), 46.12 (C17+C18), 39.90 (C14), 
28.66 (C7). UV−vis (DMSO), λmax (ε, M−1 cm−1): 263 (45000), 280 (44000), 319 (41000). 
Single crystals of HL2·C2H5OH suitable for X-ray diffraction study were obtained by slow 
evaporation of ethanolic solution of HL2 at room temperature. 
N-(9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden-N’-(1-pyridin-2-yl-
methylidene)azine (HL3). To a refluxing suspension of C (0.25 g, 0.73 mmol) in methanol 
(62 ml), 2-pyridinecarbaldehyde (0.08 g, 0.74 mmol) was added. As soon as all starting 
material had dissolved, the reaction mixture was filtered hot, cooled to room temperature and 
allowed to stand at –20 °C overnight. The yellow precipitate formed was removed by 
filtration, washed with diethyl ether and dried in vacuo. Yield: 0.21 g, 68%. Anal. Calcd for 
C22H16N5Br⋅H2O (Mr = 448.32 g/mol) (%): C, 58.94; H, 4.05; N, 15.62. Found: C, 59.23; H, 
4.17; N, 15.62. 1H NMR (DMSO-d6, δ): 11.82 (s, 1H, N12), 9.41 (s, 1H, N5), 8.59(d, 1H, 
3J(HC19) = 4.7 Hz, C18), 8.40 (d, 1H, 3J(HC20) = 8.2 Hz, C21), 8.34 (s, 1H, C15), 7.92 (s, 1H, 
C8), 7.84 (dd, 1H, 3J(HC19) = 7.3 Hz, 3J(HC21) = 7.9 Hz, C20), 7.74 (d, 1H, 3J(HC2) = 7.9 Hz, 
C1), 7.54 (d, 1H, 3J(HC3) = 7.6 Hz, C4), 7.41 (dd, 1H, 3J(HC2) = 7.5-8.5 Hz, 3J(HC4) = 8.0 Hz, 
C3), 7.39 (d, 1H, 3J(HC10) = 7.7 Hz, C11), 7.38 (dd, 1H, 3J(HC18) = 4.0 Hz, 3J(HC20) = 7.5 Hz, 
C19) 7.28 (dd, 1H, 3J(HC1) = 7.9 Hz, 3J(HC3) = 7.5-8.5 Hz, C2), 7.27 (d, 1H, 3J(HC11) = 8.5 
Hz, C10), 3.7 (s, 2H, C7); 13C{1H} NMR (DMSO-d6, δ): 160.31 (C6), 154.77 (C15), 154.25 
(C16), 149.77 (C18), 136.88 (C4a), 136.85 (C20), 136.35 (C11a), 134.74 (C12a), 128.73 
(C3), 128.63 (C7b), 127.68 (C1), 124.98 (C10), 124.81 (C19), 124.03 (C2), 124.00 (C4), 
122.95 (C12b), 121.85 (C21), 120.87 (C8), 113.90 (C11), 112.22 (C9), 109.48 (C7a), 27.66 
(C7). UV−vis (DMSO), λmax (ε, M−1 cm−1): 268 (15300), 317 (25400), 339 (22200), 462 
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(760). X-ray diffraction quality single crystals of HL3·2CH3OH were picked up directly from 
the reaction vessel. 
6-N-(2-N',N'-dimethylaminoethylenamino)-7,12-dihydroindolo[3,2-d][1]-benzazepino-
dichlorido-copper(II) [Cu(HL1)Cl2] (1). To a solution of HL1 (0.26 g, 0.81 mmol) in 
methanol (23.5 ml) under reflux, CuCl2·2H2O (0.14 g, 0.84 mmol) in methanol (1.5 ml) was 
added. The greenish-brown solution formed was refluxed for 5 min, filtered hot and allowed 
to cool to room temperature. The next day the crystals formed were removed by filtration, 
washed with methanol and dried in vacuo. Yield: 0.25 g, 69%. Anal. Calcd for 
C20H22N4Cl2Cu (Mr = 452.88 g/mol) (%): C, 53.04; H, 4.90; N, 12.37. Found: C, 53.05; H, 
4.90; N, 12.28. ESI-MS in methanol (positive): 274 [HL1−N(CH3)2]+, 319 [H2L1]+, 380 
[Cu(L1)]+, 416 [Cu(HL1)Cl]+, 440 unidentified, 454 [Cu(L1)ClK]+, 470 
[Cu(HL1)Cl(CH3O)Na]+. IR spectrum in KBr, selected bands, cm-1: 3318, 3213, 3048, 2093, 
1628, 1407, 768, 741. UV−vis (DMSO), λmax (ε, M−1 cm−1): 263 (26700), 323 (17300). Single 
crystals of 1 suitable for X-ray diffraction study were picked up directly from the reaction 
vessel. 
9-Bromo-6-N-(2-N',N'-dimethylaminoethylenamino)-7,12-dihydroindolo[3,2-d][1]-
benzazepino-dichlorido-copper(II) [Cu(HL2)Cl2] (2). To a refluxing solution of HL2 (0.20 
g, 0.51 mmol) in methanol (10 ml), a solution of CuCl2·2H2O (0.09 g, 0.52 mmol) in 
methanol (1 ml) was added. The dark-green solution formed was refluxed for 5 min, filtered 
hot and allowed to cool to room temperature. The next day the crystals formed were removed 
by filtration, washed with methanol and dried in vacuo. Yield: 0.21 g, 78%. Anal. Calcd for 
C20H21N4BrCl2Cu (Mr = 531.76 g/mol) (%): C, 45.17; H, 3,98; N, 10.54. Found: C, 44.82; H, 
4.04; N, 10.21. ESI-MS in methanol (positive): 352 [HL2−N(CH3)2]+, 397 [H2L2]+, 458 
[Cu(L2)]+, 494 [Cu(HL2)Cl]+, 518 unidentified, 532 [Cu(L2)ClK]+, 548 
[Cu(HL2)Cl(CH3O)Na]+. IR spectrum in KBr, selected bands, cm−1: 3272, 1627, 1398, 807, 
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761, 748, 626. UV-vis (DMSO), λmax (ε, M−1 cm−1): 274 (31000), 317 (21000). Single 
crystals of 2 suitable for X-ray diffraction study were picked up directly from the reaction 
vessel. 
N-(9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6-yliden)-N'-(1-pyridin-2-yl-
methylidene)-azin-5-ide-dichlorido-copper(II) [Cu(L3)Cl2]·1.5CH3OH (3). To a solution 
of HL3 (0.04 g, 0.10 mmol) in methanol (7 ml) under reflux, CuCl2·2H2O (0.019 g, 0.11 
mmol) in methanol (1 ml) was added. The yellowish-brown solution formed was filtered hot 
and allowed to cool to room temperature. The next day the crystals formed were removed by 
filtration, washed with methanol and dried in air. Yield: 0.06 g, 64%. Anal. Calcd for 
C22H16N5BrCl2Cu·1.5CH3OH (Mr = 612.81 g/mol) (%): C, 46.06; H, 3.62; N, 11.43. Found: 
C, 46.06; H, 3.33; N, 11.38. ESI-MS in methanol (positive): 430 [H2L3]+, 491 [Cu(L3)]+, 549  
[Cu(L3)ClNa]+, 573 [(L3)Cu(CH3OH)2(H2O)]+. IR spectrum in KBr, selected bands, cm-1: 
3015, 1618, 1546, 1400, 1303, 1021, 758, 738. UV-vis (DMSO), λmax (ε, M−1 cm−1): 311 
(20300), 338 (16000), 463 (9700). Single crystals of the composition 3·1.5CH3OH suitable 
for X-ray diffraction study were picked up directly from the reaction vessel. 
N-(9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6-yliden)-N'-(1-pyridin-2-yl-
ethylidene)-azin-5-ide-dichlorido-copper(II) [Cu(HL4)Cl2]·1.5H2O (4). To a suspension of 
HL4 (0.11 g, 0.25 mmol) in refluxing methanol (19 ml) a solution of CuCl2·2H2O (0.045 g, 
0.26 mmol) in methanol (1 ml) was added. The reaction mixture was refluxed for 10 min, 
filtered hot and allowed to cool to room temperature. The next day the product formed was 
removed by filtration, washed with methanol and dried in vacuo. Yield: 0.13 g, 91%. Anal. 
Calcd for C23H18N5BrCl2Cu·1.5H2O (Mr = 605.80 g/mol) (%): C, 45.60; H, 3.49; N, 11.56. 
Found: C, 45.52; H, 3.30; N, 11.19. ESI-MS in methanol (positive): 505 [Cu(L4)]+, 587 
[(HL4)Cu(CH3O)CH3OH(H2O)]+. IR spectrum in KBr, selected bands, cm-1: 3343, 3095, 
3065, 1594, 1520, 1466, 1183, 770. UV−vis (DMSO), λmax (ε, M−1 cm−1): 310 (23000), 314 
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(20000), 454 (12800). Single crystals of the composition 4·1.5H2O suitable for X-ray 
diffraction study were picked up directly from the reaction vessel. 
N-(9-Bromo-7,12-dihydroindolo-[3,2-d][1]benzazepin-6-yliden)-N'-(1-pyridin-2-yl-
ethylidene)-azin-5-ide-acetato-methanolo-copper(II) 
[Cu(L4)(CH3COO)(CH3OH)]·3CH3OH (5). To a suspension of HL4 (0.445 g, 1.0 mmol) in 
refluxing methanol (9 ml) a solution of Cu(CH3COO)2·H2O (0.100 g, 0.5 mmol) in methanol 
(7 ml) was added. The dark-brown hot solution was filtered and saturated slowly with diethyl 
ether. After 3 days the crystals formed were removed by filtration, washed with methanol and 
dried in air. Yield: 0.30 g, 84%. Anal. Calcd for C25H20N5BrO2Cu (Mr = 565.91 g/mol) (%): 
C, 53.06; H, 3.56; N, 12.38. Found: C, 52.83; H, 3.91; N, 12.76. ESI-MS in methanol 
(positive): 444 [H2L4]+, 505 [Cu(L4)]+, 527 [(L4-H)CuNa]+, 593 [HL4CuK(CH3O)H2O]+. IR 
spectrum in KBr, selected bands, cm-1: 1634, 1491, 1461, 1387, 1152, 898, 762. UV−vis 
(methanol), λmax (ε, M−1 cm−1): 233 (52600), 261 (29600), 316 (30200), 436 (8500). Single 
crystals of the composition 5·3CH3OH suitable for X-ray diffraction study were picked up 
directly from the reaction vessel. 
Physical Measurements. 1H and 13C NMR, NOE difference and two-dimensional 1H-1H 
COSY, 1H-1H TOCSY, 1H-13C HSQC and 1H-13C HMBC NMR spectra were recorded on a 
Bruker Avance III spectrometer (Ultrashield Magnet) in DMSO-d6 at 25 °C using standard 
pulse programs at 500.10 (1H) and 125.76 (13C) MHz and a Bruker Avance DPXTM 400 
spectrometer (HL2) at 400.13 (1H) and (100.63 (13C) MHz. 1H and 13C shifts are quoted 
relative to the residual solvent signals. Elemental analyses were carried out at the 
Microanalytical Service of the Institute of Physical Chemistry of the University of Vienna. 
Electrospray ionization mass spectrometry was carried out using a Bruker Esquire 3000 
instrument (Bruker Daltonic, Bremen, Germany) on samples dissolved in methanol. Infrared 
spectra were obtained as KBr pellets on a Bruker Vertex 70 FT-IR spectrometer. UV–vis 
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spectra were recorded on a Perkin Elmer Lambda 650 spectrophotometer, using samples 
dissolved in DMSO (HL1–HL4 and 1–4) and methanol (5). The aqueous solution behavior of 
HL1–HL2 and 1–4 with respect to hydrolysis was studied at 25 °C over 24 h by UV–vis 
spectroscopy in a 1.25% (v/v) DMSO-water mixture for HL1, HL2, 1 and 2, and a 10% (v/v) 
DMSO-water mixture for 3 and 4. Magnetic susceptibility measurements were conducted in 
solution on a Bruker Avance III spectrometer (Ultrashield Magnet) in DMSO-d6 at 298 K 
using the Evans method. The µeff calculated for a 0.018 M Cu(acac)2 solution in DMSO-d6 
was 1.75 µB. 
Crystallographic Structure Determination. X-ray diffraction measurements were 
performed with Nonius Kappa CCP (HL2) and Bruker X8 APEX II CCD diffractometers at 
100 or 120 K (HL2). Single crystals were positioned at 35, 35, 35, 30, 30 and 40 mm from the 
detector, and 525, 2619, 1643, 2017, 1374 and 3188 frames were measured, each for 50, 20, 
60, 60, 60 and 20 s over 1.5, 1, 1, 1, 1, 1° scan width for HL2, HL3, 1−3 and 5, respectively. 
The data were processed using the Denzo-SMN61 or SAINT software package.62 Crystal data, 
data collection parameters, and structure refinement details for HL2, HL3, 1−3 and 5 are given 
in Table 1. The structures were solved by direct methods and refined by full-matrix least-
squares techniques. Non-hydrogen atoms were refined with anisotropic displacement 
parameters. H atoms were placed at calculated positions and refined as riding atoms in the 
subsequent least-squares model refinements. The isotropic thermal parameters were estimated 
to be 1.2 times the values of the equivalent isotropic thermal parameters of the non-hydrogen 
atoms to which hydrogen atoms were bonded. SHELXS-9763 was used for structure solution 
and SHELXL-9764 for refinement, molecular diagrams were produced with ORTEP,65 and 
appropriate scattering factors were used.66 
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Cell lines and culture conditions. CH1 (ovarian carcinoma, human) cells were generously 
provided by Lloyd R. Kelland (CRC Centre for Cancer Therapeutics, Institute of Cancer 
Research, Sutton, U.K.). SW480 (colon carcinoma, human) and A549 (non-small cell lung 
cancer, human) cells were kindly provided by Brigitte Marian (Institute of Cancer Research, 
Department of Medicine I, Medical University of Vienna, Austria). Cells were grown without 
antibiotics in 75 cm2 culture flasks (Iwaki/Asahi Technoglass) as adherent monolayer cultures 
in Minimal Essential Medium (MEM) supplemented with 10% heat-inactivated fetal bovine 
serum, 1 mM sodium pyruvate and 2 mM L-glutamine (all purchased from Sigma-Aldrich). 
Human A2780 and A2780cisR cells were obtained from the European Centre of Cell Cultures 
(ECACC, Porton down, Salisbury, UK) and cell culture reagents were obtained from Gibco-
BRL (Basel, Switzerland). These cells were grown in RPMI 1640 medium containing 10% 
heat-inactivated fetal calf serum (FCS) and antibiotics. All cultures were maintained at 37 °C 
in a humidified atmosphere containing 5% CO2 and 95% air. 
Cytotoxicity determination. Cytotoxicity was determined by the colorimetric MTT assay 
(MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Sigma-Aldrich). 
For this purpose, cells were harvested from culture flasks by trypsinization and seeded in 100 
µL aliquots in the appropriate medium into 96-well microculture plates. The following cell 
densities were chosen to ensure exponential growth of untreated controls throughout the 
experiment: 1.5 × 103 (CH1), 2.5 x 103 (SW480) and 4.0 × 103 (A549) viable cells per well. 
For 24 h, cells were allowed to settle and resume exponential growth, followed by the 
addition of dilutions of the test compounds in aliquots of 100 μL/well in the same medium. 
For this purpose, the compounds (with the exception of copper chloride) were pre-dissolved 
in DMSO and then diluted with medium to a maximum DMSO content of 0.5% v/v. After 
continuous exposure for 96 or 72 h, medium was replaced by 100 μL/well RPMI 1640 
medium (supplemented with 10% heat-inactivated fetal bovine serum and 4 mM L-glutamine) 
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plus 20 μL/well solution of MTT in phosphate-buffered saline (5 mg/mL) (all purchased from 
Sigma-Aldrich). After incubation for 4 h, medium/MTT mixtures were removed, and the 
formazan product formed by viable cells was dissolved in DMSO (150 μL/well). Optical 
densities at 550 nm were measured with a microplate reader (Tecan Spectra Classic), using a 
reference wavelength of 690 nm to correct for unspecific absorption. The quantity of viable 
cells was expressed as a percentage of the untreated controls, and 50% inhibitory 
concentrations (IC50) were calculated from concentration-effect curves by interpolation. The 
evaluation is based on at least three independent experiments, each comprising three 
replicates per concentration level. 
 
Results and discussion 
The bidentate ligands HL1 and HL2 were prepared in good yield by reacting the thiones A and 
B (see Scheme 1) with N,N-dimethylethylenediamine in dry THF under reflux for 24 and 45 
h, respectively. The Paullone-hydrazine C was obtained in 85% yield by condensation of 
hydrazine hydrate with thione B in dry ethanol at reflux (Scheme 1).20 Further reaction of C 
with 2-pyridinecarbaldehyde or 2-acetylpyridine, respectively, affords the tridentate ligands 
HL3 and HL4.60 1H and 13C NMR spectra of HL3 and HL4 in DMSO-d6 revealed that both 
ligands adopt a configuration with an exocyclic C6=N13 bond (confirmed by the chemical 
shifts of C6 and presence of a proton at N5), in contrast to HL1 and HL2 with an endocyclic 
C6=N5 bond (see Experimental).59 
Complexes 1−4 were obtained in good to excellent yield (68−95%), as shown in Scheme 1, 
by reacting the corresponding ligand with CuCl2·2H2O in refluxing methanol. Complex 5 was 
obtained in 84% yield from reaction of HL4 with Cu(CH3COO)2·H2O in methanol under 
reflux. Magnetic susceptibility measurements were carried out in DMSO at 298 K for 
complexes  2 and 4 using the Evans method.67,68 The calculated effective magnetic moments 
of 1.75 and 1.74 µB, respectively, are in accord with the d9 electronic configuration of 
copper(II) with S = ½. 
The formation of the complexes was confirmed by electrospray ionization mass spectra (ESI-
MS, positive ion mode) in methanol, in which peaks that may be assigned to the ions [Cu(L1–
4)]+ with m/z values of 380 (1), 458 (2), 491 (3) and 505 (4 and 5) were observed. The 
formation of the [H2L1–4]+ ion was observed for all complexes, with the exception of 4. The 
presence of intense peaks assigned to [H2L1–4]+ ions for 1 and 2 indicate their lower stability 
compared to complexes 3 and 4 towards dissociation. In the spectra of 4 the peak attributed to 
the ion [CuL4]+ has the highest relative intensity. 
Crystal Structures. The molecular structure of HL2 established by single crystal X-ray 
diffraction is shown in Figure 1 and selected bond lengths and bond angles are given in the 
caption.  
 
Figure 1. ORTEP plot of HL2 with thermal ellipsoids drawn at the 50% probability level. 
Selected bond lengths (Å) and bond angles (deg): C11−N2 1.4141(16), C12−N2 1.3029(16), 
C12−N3 1.3460(16), C12−C17 1.5132(17), C17−C18 1.4954(17), C5−C18 1.3750(17), 
C5−C6 1.4592(17), C6−C11 1.4221(18) Å; ΘN1−C5−C6−C7 36.84(18), ΘN3−C13−C14−N4 48.20(15)°.  
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Complexes 1 and 2 (Fig. 2) crystallized in the monoclinic space group P21/n and triclinic 
centrosymmetric space group 1P , respectively. 
 
Figure 2. ORTEP plots for [Cu(HL1)Cl2] (1) (left) and [Cu(HL2)Cl2] (2) (right) with thermal 
ellipsoids drawn at the 50% probability level. Selected bond lengths (Å) and bond angles 
(deg) for 1: Cu−Cl1 2.2715(9), Cu−Cl2 2.1965(10), Cu−N3 1.948(3), Cu−N4 2.021(3), 
C12−N2 1.347(4), C12−N3 1.301(4) Å; Cl1−Cu−N3 96.70(9), Cl1−Cu−N4 132.32(9), 
Cl2−Cu−N3 148.97(9), Cl2−Cu−N4 103.92(9), N3−Cu−N4 82.62(11) °; ΘN1−C5−C6−C7 
33.08(5), ΘN3−C13−C14−N4 33.8(4); and for 2: Cu−Cl1 2.2736(7), Cu−Cl2 2.2085(7), Cu−N3 
1.975(2), Cu−N4 2.034(2), C12−N2 1.359(3), C12−N3 1.302(3) Å; Cl1−Cu−N3 96.96(6), 
Cl1−Cu−N4 147.45(6), Cl2−Cu−N3 151.99(6), Cl2−Cu−N4 96.72(6), N3−Cu−N4 81.77(9) °; 
ΘN1−C5−C6−C7 −35.3(4), ΘN3−C13−C14−N4 −32.4(3)°. 
 
The copper(II) center in 1 and 2 is four-coordinate, and as expected, the ligands HL1 and HL2 
are bound to the metal via two nitrogen atoms N3 and N4 of the ethylendiamine moiety. The 
remaining two binding sites are occupied by two chlorido ligands. The Cu–N and Cu–Cl 
distances are typical of those of other ethylenediamine derivatives of copper(II) chloride (e.g. 
[Cu(ethylenediamine)Cl2]69 Cu–N 2.010(5) and 2.017(5) Å, Cu–Cl 2.286(2) and 2.301(2) Å; 
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[Cu(trans-N, N, N´,N´-tetramethylcyclohexane-1,2-diamine)Cl270 Cu–N 2.052(7), Cu–Cl 
2.247(2) Å; [Cu(N-4-hydroxybenzylmethyl-N,N´,N´-trimethylethylenediamine)Cl2]71 Cu–N 
2.086(3) and 2.045(3) Å, Cu–Cl 2.263(1) and 2.269(1) Å. The coordination geometry can be 
described as a distorted tetrahedron. The distortion from the square-planar geometry in 1 and 
2 may be estimated by the dihedral angle between the planes CuN3N4 and CuCl1Cl2, which 
deviates tremendously from 0° (55.8 and 41.7° for 1 and 2, respectively). 
The conformation of the coordinated ligand HL2 differs to that adopted by the metal-free 
ligand (Fig. 1). This is evident when comparing the torsion angle ΘN1−C5−C6−C7 in metal-free 
HL2 at 36.84 and in coordinated HL2 in 2 at −35.3(4)°, which are of similar magnitude, but 
opposite sign. The ligand backbone mainly consists of sp2-hybridized carbon and nitrogen 
atoms. The only exception is the methylene group carbon atom in the seven-membered 
azepine ring, which is sp3-hybridized. This atom disrupts the conjugation of the whole π-
system, and as a result the ligand as a whole is nonplanar. Binding to copper(II) is 
accompanied by rotation around the C5−C6 bond (Fig. 1), enabling azepine ring inversion 
and rotation of the dimethylamine group around the C13−C14 bond by 80.6°. It is also 
noteworthy that the distribution of electron density over the fragment N2–C12–N3 in 2 with 
an exocyclic C=N bond is opposite to that in the metal-free ligand HL2 with an endocyclic 
C=N bond. The combined effect of these structural modifications possibly destabilize 
(weaken) the binding of the ethylenediamine-part of the ligand to the metal thereby reducing 
the overall stability of the complex in solution, notably in water which is nucleophilic (see 
below). 
The crystal structure of 2 consists of molecules that are involved in two intermolecular 
hydrogen bonding interactions, namely N1−H···Cl1i [N1−H 0.88, H···Cl1i 2.371, N1···Cl1i 
3.234 Å, N1−H···Cl1i 166.97] and N2−H···Clii [N2−H 0.88, H···Cl1ii 2.625, N2···Cl1ii 3.416 
Å, N2−H···Cl1ii 150.06], see Fig. S1. 
The solid state structures of HL3, 3 and 5 are shown in Figures 3−5, respectively. Selected 
bond distances (Å) and bond angles (deg) are given in the legends to Figures. The tridentate 
ligand HL3 crystallized in the monoclinic space group P21/c with two molecules of methanol. 
Intermolecular H-bonding interactions of the type O−H···N are evident between lattice 
methanol molecules and HL3, namely O2···H−N12 (O2···H 1.920, O6···N12 2.780, H−N12 
0.88 Å, O6···H−N12 165.24°), O2−H···N13 (O2−H 0.84, O2−N13 2.734, N13···H 1.911 Å, 
O2−H···N13 166.00°), O1···H−N5 (O1···H 2.144, O1···N5 3.010, H−N12 0.88 Å, O1···H−N12 
168.17°), O1−H···N14 (O1−H 0.84, O1···N14 3.026, H···N14 2.497 Å, O1−H···N14 121.81°), 
O1−H···N17 (O1−H 0.84, O1···N17 2.904, H···N17 2.101 Å, O1−H···N17 159.92°). The 
distribution of electron density over the fragment N5−C6−N13 [C6−N5 1.358(5), C6−N13 
1.309(5) Å] indicates the presence of an exocyclic double bond at the amidrazone moiety, 
which is in accordance with 1H and 13C NMR data for HL3. 
 
Figure 3. ORTEP plot of HL3 with thermal ellipsoids drawn at the 50% probability level. 
Selected bond lengths (Å) and bond angles (deg): C4a−N5 1.410(5), C6−N5 1.358(5), 
C6−N13 1.309(5), N13−N14 1.399(5), N14−C15 1.274(6) Å; ΘN5−C6−N13−N14 −1.5(5), 
ΘC4a−N5−C6−C7 −2.6(7), ΘN12−C12a−C12b−C1 34.0(6)°. 
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Complex 3 crystallized in the monoclinic space group P21/c with 0.75 molecules of lattice 
water. As expected, HL3 acts as a neutral tridentate ligand in 3. Copper(II) is coordinated via 
the azepine ring nitrogen atom N5, the hydrazine group nitrogen atom N14, and the pyridine 
ring nitrogen atom N17. 
  
Figure 4. ORTEP plot of [Cu(HL3)Cl2] (3) with thermal ellipsoids drawn at the 50% 
probability level. Selected bond lengths (Å) and bond angles (deg): Cu−N5 2.038(3),  
Cu−N14 1.982(3), Cu−N17 2.062(3), Cu−Cl1 2.2411(8), Cu−Cl2 2.4306(8), C6−N5 1.296(4), 
C6−N13 1.366(4), N13−N14 1.353(3); N5−Cu−N17 155.53(10), N14−Cu−Cl2 103.39(7),  
N14−Cu−Cl1 149.67(8), Cl1−Cu−Cl2 106.63(3), N5−Cu−Cl2 100.75(7), N5−Cu−Cl1 
100.01(7), N14−Cu−N17 77.75(10), N17−Cu−Cl2 89.52(7), N17−Cu−Cl1 98.18(7).  
 
Complex 5 crystallized in the triclinic centrosymmetric space group 1P  (5) with three 
molecules of methanol in the asymmetric unit, involved in strong intermolecular H-bonding 
interactions of the type O−H···O between lattice methanol molecules [O6···O5(x − 1, y, z) 
2.772, O4···O5(−x + 2, −y + 2, −z + 1) 2.892 Å], between lattice methanol molecules and 5, 
namely O6···H−N12 (O6···H 1.913, O6···N12 2.760, H−N12 0.88 Å, O6···H−N12 160.89°), 
O5−H···O2(x + 1, y, z) with O5−H 0.84, H···O2 1.844, O5···O2 2.651 Å, O5−H···O2 160.53° 
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and between molecules of 5 of the type O3−H···N13(−x + 1, −y + 1, −z + 1) with O3−H 0.833, 
H···N13 1.970, O3···N13 2.795 Å, O3−H···N13 170.16° (Figure S2). As expected, HL4 acts as 
a neutral tridentate ligand in 4 and as a monodeprotonated ligand in 5, coordinating to 
copper(II) via the azepine ring nitrogen atom N5, the hydrazine group nitrogen atom N14, and 
the pyridine ring nitrogen atom N17. The copper(II) center is five-coordinate, the remaining 
two binding sites being occupied by two chloride ligands in 3 or by two different ligands, an 
acetate ion (atom O1) and a methanol (atom O3), in 5.  
 
Figure 5. ORTEP plot of [Cu(L4)(CH3COO)(CH3OH)] (5) with thermal ellipsoids drawn at 
the 50% probability level. Selected bond lengths (Å) and bond angles (deg): Cu−N5 
1.9994(17),  Cu−N14 1.9482(18), Cu−N17 2.0363(18), Cu−O1 1.9392(15), Cu−O3 
2.2794(15), C6−N5 1.324(3), C6−N13 1.351(3), N13−N14 1.372(2); N5−Cu−N17 158.21(7), 
N14−Cu−O1 173.26(7),  N14−Cu−O3 96.86(6), O1−Cu−O3 88.73(6), N5−Cu−O1 103.89(7), 
N5−Cu−O3 96.38(6), N14−Cu−N17 79.92(7), N17−Cu−O1 96.12(7), N17−Cu−O3 92.55(6).  
 
The τ-descriptor for five-coordinate complexes expressed as the difference between the 
angles N5−Cu−N17 155.53(10) and N14−Cu−Cl1 149.67(8) divided by 60 gives a value of  
0.10 for 3, which is very close to the ideal one for a square pyramid (0).72 Note that this value 
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in the five-coordinate gallium(III) complex [Ga(L4)Cl2]60 is between that for a trigonal 
bipyramid (1) and that for a square pyramid (0) at 0.52. The angles between the mean plane of 
the indole moiety and the benzene ring annelated to the seven-membered azepine ring in 3 
and 5 are 39.6 and 36.7°, respectively. These values are close to those in the metal-free 
ligands HL3 (35.0°) and HL4 (34.0°), and in Ga(L4)Cl2 (33.6°). In contrast the angle between 
the indole and the pyridine ring in 3 is 78.6° and in 5 is 83.6°, differing by ca. 54 and 49°, 
respectively, from that in the metal-free ligand HL4 (132.56°) and by ca. 38 and 33°, 
respectively, to that in metal-free ligand HL3 (116.39°). In contrast to HL4, the bond lengths 
C6−N5 [1.324(3) Å] and C6−N13 [1.351(3) Å] differ from one another to a lesser extend and 
indicate a delocalized π-system, which also extends over the N13−N14 [1.372(2) Å] bond in 
5. The distribution of electron density over the fragment N5−C6−N13 [C6−N5 1.3621(16), 
C6−N13 1.3088(16) Å] indicates the presence of an exocyclic double bond at the amidrazone 
moiety. The lack of a proton at N13 is corroborated by the role of the amidrazone moiety as a 
proton acceptor from the coordinated methanol of the neighbouring molecule with formation 
of the hydrogen bond N13···H−O3 in 5. The τ-descriptor for 5, expressed as the difference 
between the angles N14−Cu−O1 173.26 and N5−Cu−N17 158.21 divided by 60, gives a value 
of 0.25, which is close to the ideal value for a square pyramid (0).72 
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Stability studies. The kinetic stability of the complexes in aqueous solution with a DMSO 
content of 1.25% v/v (1 and 2) or 10% v/v (3 and 4) was studied by UV−vis spectroscopy 
over 24 h. For 1 and 2 the resulting spectra were compared with those of the ligands HL1 and 
HL2 (Figures S3 and S4). A weak charge-transfer band at 397 nm (Figures S5 and S6) with a 
molar extinction coefficient of ca. 570 M−1cm−1, resulting from coordination of 
ethylenediamine moiety to copper(II) ion, seems to be responsible for the yellow color of the 
methanol solutions of 1 and 2. As the spectra of 1 and 2 are very similar to those of the 
corresponding ligands, no clear statement can be made whether 1 and 2 dissociate or 
hydrolyze during the measurements in aqueous DMSO solution. However, ESI mass spectra 
of 1 and 2 in a methanolic solution with 10% water measured 24 h after dissolution showed 
the presence of peaks with m/z values of 319 and 397, attributable to [H2L1]+ and [H2L2]+ 
correspondingly, indicating their dissociation or hydrolysis. In contrast, on coordination of 
ligands HL3 and HL4 to copper(II) via the pyridine nitrogen atom, the hydrazine nitrogen and 
the azepinone ring nitrogen atom alters significantly the conjugated π-systems of the yellow 
colored ligands HL3 and HL4, resulting in significantly different electronic absorption spectra. 
As a result, solutions of 3 and 4 show significant absorbances in the visible range, namely a 
broad charge-transfer band at 430 and 420 nm, respectively (Fig. S7). These bands are blue-
shifted by 29 and 27 nm for 3 and 4, respectively, when DMSO as solvent is replaced by 
water with a content of 10% DMSO (v/v). A small decrease in absorption (ca. 4%) for 3 and 4 
was observed over the first 4 h, with no further changes over the next 20 h, indicating that the 
coordination sphere of copper(II) remained intact.  
Biological studies. The cytotoxicity of 1, HL1, 2, HL2, 3 and 4 was assessed by means of a 
colorimetric microculture assay (MTT assay) in three human cancer cell lines (A549, SW480, 
CH1). Additionally, complexes 1, 2 and 4 were tested in an isogenic pair of cell lines, one 
being sensitive to cisplatin (A2780) and the other having acquired cisplatin resistance 
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(A2780cisR). The compounds showed the strongest effects on cell viability on the more 
chemosensitive ovarian carcinoma cell line CH1, whereas the more chemoresistant non-small 
cell lung cancer cell line A549 is the least sensitive for this series of compounds. The IC50 
values are listed in Table 2, and the concentration-effect curves in three cell lines are depicted 
in Figures 6 and 7, from which certain structure-activity relationships can be discerned (see 
below). 
The Paullone derived ligands HL1 and HL2 show notable cytotoxicities with IC50 values in the 
10−6 or 10−5 M range. Substitution by bromine at position 9 of the Paullone scaffold has a 
favorable effect on cytotoxicity, as reflected by the significantly lower IC50 values of the HL2 
ligand. Previously this substitution has been reported to increase CDK-inhibitory potency, but 
apparently without being reflected in an enhanced cytotoxicity.14 Complexation of the 
Paullones HL1 and HL2 with copper(II) results in only a modest increase in cytotoxicity. Only 
in CH1 cells is a clear-cut advantage of complexation of the HL1 ligand with a significant 
improvement in cytotoxicity observed. Nevertheless, activity is maintained in the complexes, 
and other advantages relevant for the in vivo applications arise from their higher solubility 
and/or altered pharmacokinetic behavior. Comparison of the complexes 1 and 2 shows that 
bromination of the ligand at C9 results in a higher cytotoxicity, depending on the cell line 
(with the exception of A2780), roughly paralleling the effects in the uncomplexed Paullone 
derivatives (Figure 6). 
The cytotoxic potencies of HL3 and HL4 could not be determined because of insufficient 
solubility, and while the compounds mentioned above show IC50 values in micromolar 
concentrations, complexes 3 and 4 exhibit cytotoxicities mainly in the nanomolar range. Thus, 
the structural modifications of the chelating side chain result in 4.7–12 and 11–33 times 
higher cytotoxicity, respectively, compared to complex 2. As the cytotoxicities of HL3 and 
HL4 could not be determined because of insufficient solubility, it cannot be assessed whether 
the modification of the side chain itself or the consequences for binding to copper, i.e. a 
tridentate coordination involving N5 of the azepine ring, accounts for the increase in activity. 
Thus, it remains unclear whether the effects of complexes 3 and 4 are governed by those of 
the ligands HL3 and HL4 to the same extent as the effects of 2 are by those of HL2 or whether 
coordination to copper adds a more substantial component to overall activity in these cases. 
However, it is not unreasonable to assume that HL1, HL2, 1 and 2 exhibit similar 
cytotoxicities as the copper ion is released from the bidentate ligand whereas in 3 and 4 
stronger coordination leads to an enhancement in activity. It is worth noting that the IC50 
values of CuCl2 range between 43 and > 160 µM and are thus one order of magnitude higher 
than those of the least cytotoxic complex (Table 2). If copper ions were partially released 
from the complexes at any stage of exposure, they are unlikely to contribute appreciably to 
the overall effects. 
At least for the copper(II) complexes, the methyl substitution in position 15 of the Paullone 
ligand is favorable in terms of biological activity, as indicated by the lower IC50 values of 
complex 4 compared to 3, yielding the most cytotoxic compound within the series (Figure 7). 
The acquired cisplatin resistance of the ovarian cancer cell line A2780cisR affects sensitivity 
to complexes 1, 2 and 4 to only a moderate extent, as indicated by slightly higher IC50 values 
than in the parent A2780 cell line (Table 2). As resistance in A2780cisR cells does not 
exclusively pertain to DNA cross-linking agents and can only partially be attributed to 
increased DNA repair capacity,73 DNA-damaging effects cannot be inferred unequivocally 
from these data, but should be considered in future mechanistic studies of the copper(II) 
complexes. 
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Table 2. Cytotoxicity of Paullone-based ligands, their copper(II) complexes and CuCl2 in 
human cancer cell lines. 
Compound IC50 (µM)a 
 A549 a SW480 a CH1 a A2780 b A2780cisR b 
HL1 44 ± 1 25 ± 1 21 ± 3 – – 
HL2 8.2 ± 1.0 4.5 ± 0.4 3.0 ± 0.4 – – 
1 39 ± 5 12 ± 2 3.2 ± 0.2 3.6 ± 0.4 10 ± 1 
2 9.9 ± 1.3 4.0 ± 0.4 1.6 ± 0.04 4.0 ± 0.2 5.2 ± 0.5 
3 1.2 ± 0.2 0.33 ± 0.06 0.34 ± 0.06 – – 
4 0.35 ± 0.04 0.12 ± 0.004 0.050 ± 0.003 0.19 ± 0.04 0.49 ± 0.05 
CuCl2 153 ± 8 > 160 43 ± 3 – – 
 
50% inhibitory concentrations (means ± standard deviations from at least three independent 
experiments), as obtained by the MTT assay (exposure for a 96 h, or b 72 h). 
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Figure 6. Concentration-effect curves of complexes 1 and 2 in comparison with the 
corresponding uncomplexed Paullone derivatives HL1 and HL2 in the human cancer cell lines 
A549 (A), SW480 (B) and CH1 (C), obtained by the MTT assay following continuous 
exposure for 96 h. 
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Figure 7. Concentration-effect curves of complexes 2, 3 and 4 in the human cancer cell lines 
A549 (A), SW480 (B) and CH1 (C), obtained by the MTT assay following continuous 
exposure for 96 h. 
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Final remarks. Complexation of copper(II) salts with bidentate and tridentate Paullone-based 
ligands HL1−2 and HL3−4 modified at the lactone function resulted in four-coordinate (1 and 2) 
and five-coordinate (3−5) copper(II) complexes, which show markedly different, but 
remarkably high, antiproliferative activities in human cancer cell lines with IC50 values in the 
micromolar (1, 2) or in the nanomolar (3, 4) concentration range. The high cytotoxicity of the 
metal-free Paullones HL1−2 is at least preserved upon binding to copper(II) or even enhanced, 
as in the case of HL1 and 1 in CH1 cells. It should be also stressed that the biological activity 
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of metal-free Paullones HL3−4 could not be assayed because of their very low solubility in 
biocompatible media. Coordination to copper(II) improved the solubility of the resulted 
species, enabling them to be used as anticancer agents. It is highly probable that for 3 and 4 
the copper(II) center remains attached to the Paullone ligands until entry into the cells, 
although it remains to be established whether the metal ion is cleaved once inside the cell. 
Further experiments are in progress to delineate the mode of action of these compounds. The 
fact that 3 and 4 are highly cytotoxic, at nanomolar concentrations, could allow their 
application at very low doses which could offer a significant advantage over platinum-based 
chemotherapies. 
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Figure S1. Part of the crystal structure of 2, showing the intermolecular hydrogen bonding interactions. 
Symmetry codes: (i) x + 1, y, z; (ii) −x, −y, −z. 
 
 
 
 
 
 
 
Figure S2. Part of the crystal structure of 5·3CH3OH, showing the intermolecular hydrogen bonding 
interactions. Symmetry codes: (i) x + 1, y, z; (ii) −x, −y, −z. 
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Figure S3. Time dependent UV-vis spectra of the ligand HL1 (top) and complex 1 (bottom) in 1.25% 
v/v DMSO/H2O. The spectra were measured immediately after dissolution (dark blue), after 4 h 
(magenta), 8 h (yellow), 12 h (turquoise), 16 h (violet), 20 h (brown) and 24 h (green). 
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Figure S4. Time dependent UV-vis spectra of the ligand HL2 (top) and complex 2 (bottom) in 1.25% 
v/v DMSO/H2O. The spectra were measured immediately after dissolution (dark blue), after 4 h 
(magenta), 8 h (yellow), 12 h (turquoise), 16 h (violet), 20 h (brown) and 24 h (green). 
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Figure S5: Charge-transfer bands of 1 mM solutions of complexes 1 (left, blue) and 2 (right, blue) in 
methanol compared to those of the corresponding ligands HL1 (left, red) and HL2 (right, red) in 
methanol. 
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Figure S6. UV-vis spectra of 1 (top, blue) and 2 (bottom, blue). The first derivatives (green in both 
cases) were used to characterize shoulders (maxima of the first derivatives). 
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Figure S7. Time dependent UV-vis spectra of the complexes 3 (above) and 4 (below) in 10% v/v 
DMSO/H2O. The spectra displayed were recorded immediately after dissolution (dark blue), after 4 h 
(magenta), 8 h (yellow), 12 h (turquoise), 16 h (violet), 20 h (brown) and 24 h (green). 
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